Patents Represented by Attorney, Agent or Law Firm Nancy A. Oleski
  • CD45 disrupted nucleic acid
    Patent number: 6664107
    Abstract: A mammal lacking expression of particular CD45 isoform in certain cells of the immune system is provided. The mammal may optionally contain a transgene encoding the CD45RO isoform. Also provided are methods of using these mammals.
    Type: Grant
    Filed: February 2, 1994
    Date of Patent: December 16, 2003
    Assignee: Ontario Cancer Institute, University Health Network
    Inventors: Tak Wah Mak, Kenji Kishihara
  • Transgenic mice comprising CD45 knockout
    Patent number: 6552246
    Abstract: A mammal lacking expression of particular CD45 isoform in certain cells of the immune system is provided. The mammal may optionally contain a transgene encoding the CD45RO isoform. Also provided are methods of using these mammals.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: April 22, 2003
    Assignee: University Health Network
    Inventors: Tak Wah Mak, Josef Martin Penninger
  • Genes encoding LSIRF polypeptides
    Patent number: 6369202
    Abstract: Disclosed are nucleotide sequences encoding a novel polypeptide termed LSIRF. Also disclosed are methods of preparing the polypeptide and uses thereof.
    Type: Grant
    Filed: May 1, 2000
    Date of Patent: April 9, 2002
    Assignee: Amgen Canada Inc.
    Inventors: Toshifumi Matsuyama, Alex Grossman, Christopher Donald Richardson
  • DKR polypeptides
    Patent number: 6344541
    Abstract: Disclosed are nucleic acid molecules encoding novel DKR polypeptides. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.
    Type: Grant
    Filed: September 25, 1998
    Date of Patent: February 5, 2002
    Assignee: Amgen Inc.
    Inventors: Michael Brian Bass, John Kevin Sullivan, Lars Eyde Theill, Daguang Wang
  • Agouti and agouti-related peptide analogs
    Patent number: 6303749
    Abstract: The present invention provides peptides related to agouti signaling protein and agouti related protein which are useful in modulating the activity of the melanocortin 3 and melanocortin 4 receptors. Also provided are methods of preparing the peptides, as well as nucleic acid molecules encoding the peptides.
    Type: Grant
    Filed: January 29, 1999
    Date of Patent: October 16, 2001
    Assignee: Amgen Inc.
    Inventor: Mark Anthony Jarosinski
  • Tissue specific transgene expression
    Patent number: 6268212
    Abstract: This invention provides a mammal with enhanced liver expression of a transgene. Also provided are 1) a nucleic acid sequence useful in enhancing liver specific expression of a transgene, and 2) a vector containing this nucleic acid sequence.
    Type: Grant
    Filed: March 31, 1994
    Date of Patent: July 31, 2001
    Assignee: Amgen Inc.
    Inventor: William Scott Simonet
  • LSIRF polypeptides
    Patent number: 6258935
    Abstract: Disclosed are nucleotide sequences encoding a novel polypeptide termed LSIRF. Also disclosed are methods of preparing the polypeptide and uses thereof.
    Type: Grant
    Filed: November 19, 1998
    Date of Patent: July 10, 2001
    Assignee: Amgen Canada Inc.
    Inventors: Toshifumi Matsuyama, Alex Grossman, Christopher Donald Richardson
  • Agouti-related transcript antibodies and methods of use
    Patent number: 6203995
    Abstract: Disclosed is a novel gene termed ART which is expressed primarily in selected regions of the brain, as well as adrenal and lung tissues. Polypeptides encoded by ART are also disclosed, as are methods for preparing ART DNA and amino acid sequences.
    Type: Grant
    Filed: June 29, 1999
    Date of Patent: March 20, 2001
    Assignee: Amgen Inc.
    Inventor: Kevin Lee Stark
  • Genes encoding telomerase protein 1
    Patent number: 6174703
    Abstract: Disclosed are nucleic acid molecules encoding polypeptides that specifically bind telomerase RNA. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.
    Type: Grant
    Filed: November 2, 1998
    Date of Patent: January 16, 2001
    Assignees: Amgen Inc., Amgen Canada Inc.
    Inventors: Lea Anne Harrington, Murray O. Robinson
  • Cyclin E genes and proteins
    Patent number: 6165753
    Abstract: Disclosed are nucleic acid molecules encoding novel cyclin E2 polypeptides. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.
    Type: Grant
    Filed: December 30, 1998
    Date of Patent: December 26, 2000
    Assignee: Amgen Inc.
    Inventors: Steven Roy Coats, Michael Brian Bass, Murray O. Robinson
  • Enhanced solubility of recombinant proteins
    Patent number: 6077689
    Abstract: Disclosed are methods for improving the solubility of a protein of interest produced recombinantly by expressing the protein of interest as a fusion protein with a member of the 14-3-3 family of proteins.
    Type: Grant
    Filed: December 24, 1997
    Date of Patent: June 20, 2000
    Assignee: Amgen Inc.
    Inventor: Marshall Davenport Snavely
  • Agouti-related proteins
    Patent number: 6060589
    Abstract: Disclosed is a novel gene termed ART which is expressed primarily in selected regions of the brain, as well as adrenal and lung tissues. Polypeptides encoded by ART are also disclosed, as are methods for preparing ART DNA and amino acid sequences.
    Type: Grant
    Filed: March 2, 1998
    Date of Patent: May 9, 2000
    Assignee: Amgen Inc.
    Inventors: Kevin Lee Stark, Roland Luethy
  • Nucleic acids encoding myocardial peptides
    Patent number: 6034230
    Abstract: Disclosed are novel peptides that modulate inflammatory heart disease. Also disclosed are DNA molecules encoding the peptides, and methods of making the peptides.
    Type: Grant
    Filed: May 3, 1999
    Date of Patent: March 7, 2000
    Assignee: Amgen Canada Inc.
    Inventors: Kurt Bachmaier, Andrew John Hessel, Nickolaus Neu, Josef Martin Penninger
  • Genes encoding telomerase protein 1
    Patent number: 5981707
    Abstract: Disclosed are nucleic acid molecules encoding polypeptides that specifically bind telomerase RNA. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.
    Type: Grant
    Filed: April 15, 1998
    Date of Patent: November 9, 1999
    Assignees: Amgen Inc., Amgen Canada Inc.
    Inventors: Lea Anne Harrington, Murray O. Robinson
  • Cyclin E genes and proteins
    Patent number: 5973119
    Abstract: Disclosed are nucleic acid molecules encoding novel cyclin E2 polypeptides. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.
    Type: Grant
    Filed: June 5, 1998
    Date of Patent: October 26, 1999
    Assignee: Amgen Inc.
    Inventors: Steven Roy Coats, Michael Brian Bass, Murray O. Robinson
  • Peptides capable of modulating inflammatory heart disease
    Patent number: 5962636
    Abstract: Disclosed are novel peptides that modulate inflammatory heart disease. Also disclosed are DNA molecules encoding the peptides, and methods of making the peptides.
    Type: Grant
    Filed: August 12, 1998
    Date of Patent: October 5, 1999
    Assignee: Amgen Canada Inc.
    Inventors: Kurt Bachmaier, Andrew John Hessel, Nickolaus Neu, Josef Martin Penninger
  • Genes encoding telomerase protein 1
    Patent number: 5919656
    Abstract: Disclosed are nucleic acid molecules encoding polypeptides that specifically bind telomerase RNA. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.
    Type: Grant
    Filed: November 15, 1996
    Date of Patent: July 6, 1999
    Assignees: Amgen Canada Inc., Amgen Inc.
    Inventors: Lea Anne Harrington, Murray O. Robinson
  • Genes encoding LSIRF polypeptides
    Patent number: 5891666
    Abstract: Disclosed are nucleotide sequences encoding a novel polypeptide termed LSIRF. Also disclosed are methods of preparing the polypeptide and uses thereof.
    Type: Grant
    Filed: April 3, 1996
    Date of Patent: April 6, 1999
    Assignee: Amgen Canada Inc.
    Inventors: Toshifumi Matsuyama, Alex Grossman
  • Neurogene
    Patent number: 5859197
    Abstract: Disclosed are DNA and amino acid sequences for a novel polypeptide termed Neuritin which is expressed primarily in selected regions of the brain.
    Type: Grant
    Filed: October 9, 1997
    Date of Patent: January 12, 1999
    Assignees: Amgen Inc., Yeda Research & Development Co, Ltd.
    Inventors: Lars E. Theill, Gregory S. Naeve, Yoav Citri, deceased
  • Neurogene
    Patent number: 5817784
    Abstract: Disclosed are DNA and amino acid sequences for a novel polypeptide termed Neuritin which is expressed primarily in selected regions of the brain.
    Type: Grant
    Filed: August 9, 1996
    Date of Patent: October 6, 1998
    Assignees: Amgen Inc., Yeda Research and Development Co., Ltd.
    Inventors: Lars Eyde Theill, Gregory Scott Naeve, Yoav Citri, deceased